Erik SjÃ¶gren

List of Publications by Year
in descending order

52	1,892	236925 25	254184 43
papers	citations	h-index	g-index

54	54	54	1858
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PBPK models for the prediction of in vivo performance of oral dosage forms. European Journal of Pharmaceutical Sciences, 2014, 57, 300-321.	4.0	263
2	In vivo methods for drug absorption â€“ Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. European Journal of Pharmaceutical Sciences, 2014, 57, 99-151.	4.0	226
3	In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: Application of the mechanistic absorption model GI-Sim. European Journal of Pharmaceutical Sciences, 2013, 49, 679-698.	4.0	141
4	Direct In Vivo Human Intestinal Permeability (Peff) Determined with Different Clinical Perfusion and Intubation Methods. Journal of Pharmaceutical Sciences, 2015, 104, 2702-2726.	3.3	83
5	Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Linkâ€”a Workshop Summary Report. AAPS Journal, 2019, 21, 29.	4.4	70
6	In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically Based Absorption Models. Molecular Pharmaceutics, 2016, 13, 1763-1778.	4.6	67
7	Open Systems Pharmacology Communityâ€”An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 878-882.	2.5	58
8	Regional Intestinal Permeability of Three Model Drugs in Human. Molecular Pharmaceutics, 2016, 13, 3013-3021.	4.6	57
9	Human in Vivo Regional Intestinal Permeability: Quantitation Using Site-Specific Drug Absorption Data. Molecular Pharmaceutics, 2015, 12, 2026-2039.	4.6	52
10	Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report. AAPS Journal, 2018, 20, 93.	4.4	51
11	In Vivo Mechanisms of Intestinal Drug Absorption from Aprepitant Nanoformulations. Molecular Pharmaceutics, 2017, 14, 4233-4242.	4.6	49
12	In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context. Molecular Pharmaceutics, 2017, 14, 1307-1314.	4.6	48
13	Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile. Cancers, 2019, 11, 1024.	3.7	41
14	The Multiple Depletion Curves Method Provides Accurate Estimates of Intrinsic Clearance (CL_{int}), Maximum Velocity of the Metabolic Reaction (V_{max}), and Michaelis Constant (K_m): Accuracy and Robustness Evaluated through Experimental Data and Monte Carlo Simulations. Drug Metabolism and Disposition, 2009, 37, 47-58.	3.3	38
15	Concomitant intake of alcohol may increase the absorption of poorly soluble drugs. European Journal of Pharmaceutical Sciences, 2015, 67, 12-20.	4.0	38
16	The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs. International Journal of Pharmaceutics, 2018, 547, 158-168.	5.2	38
17	InÂVitro Release Mechanisms of Doxorubicin From a Clinical Bead Drug-Delivery System. Journal of Pharmaceutical Sciences, 2016, 105, 3387-3398.	3.3	37
18	Regional Intestinal Permeability in Rats: A Comparison of Methods. Molecular Pharmaceutics, 2017, 14, 4252-4261.	4.6	37

#	Article	IF	Citations
19	Preclinical Effect of Absorption Modifying Excipients on Rat Intestinal Transport of Model Compounds and the Mucosal Barrier Marker ⁵¹Cr-EDTA. Molecular Pharmaceutics, 2017, 14, 4243-4251.	4.6	34
20	Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms. Molecular Pharmaceutics, 2016, 13, 3022-3033.	4.6	32
21	Pulmonary absorption â€“ estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 124, 1-12.	4.3	31
22	Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems. Therapeutic Delivery, 2014, 5, 447-466.	2.2	30
23	In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma. Molecular Pharmaceutics, 2017, 14, 448-458.	4.6	30
24	Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report. Journal of Pharmaceutical Sciences, 2021, 110, 594-609.	3.3	27
25	Excised segments of rat small intestine in Ussing chamber studies: A comparison of native and stripped tissue viability and permeability to drugs. International Journal of Pharmaceutics, 2016, 505, 361-368.	5.2	26
26	In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma. Cells, 2021, 10, 1717.	4.1	25
27	The Pharmacokinetics and Hepatic Disposition of Repaglinide in Pigs: Mechanistic Modeling of Metabolism and Transport. Molecular Pharmaceutics, 2012, 9, 823-841.	4.6	24
28	Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model. Molecular Pharmaceutics, 2019, 16, 3053-3064.	4.6	23
29	A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition. Molecular Pharmaceutics, 2017, 14, 686-698.	4.6	21
30	Pharmacokinetics of an Injectable Modified-Release 2-Hydroxyflutamide Formulation in the Human Prostate Gland Using a Semiphysiologically Based Biopharmaceutical Model. Molecular Pharmaceutics, 2014, 11, 3097-3111.	4.6	19
31	Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugsâ€"a fenofibrate case example. International Journal of Pharmaceutics, 2014, 473, 356-365.	5.2	19
32	InÂVitro Biopredictive Methods: A Workshop Summary Report. Journal of Pharmaceutical Sciences, 2021, 110, 567-583.	3.3	18
33	Pulmonary drug absorption and systemic exposure in human: Predictions using physiologically based biopharmaceutics modeling. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 191-202.	4.3	16
34	Drug Absorption Parameters Obtained Using the Isolated Perfused Rat Lung Model Are Predictive of Rat In Vivo Lung Absorption. AAPS Journal, 2020, 22, 71.	4.4	16
35	Lipiodol-based emulsions used for transarterial chemoembolization and drug delivery: Effects of composition on stability and product quality. Journal of Drug Delivery Science and Technology, 2019, 53, 101143.	3.0	14
36	The Effects of Lipiodol and Cyclosporin A on the Hepatobiliary Disposition of Doxorubicin in Pigs. Molecular Pharmaceutics, 2014, 11, 1301-1313.	4.6	9

#	Article	IF	Citations
37	Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models. ADMET and DMPK, 2020, 8, 375-390.	2.1	8
38	Online capillary solid phase extraction and liquid chromatographic separation with quantitative tandem mass spectrometric detection (SPE-LCâ€“MS/MS) of ximelagatran and its metabolites in a complex matrix. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 291-297.	2.3	7
39	Optimal Experimental Design for Assessment of Enzyme Kinetics in a Drug Discovery Screening Environment. Drug Metabolism and Disposition, 2011, 39, 858-863.	3.3	7
40	Porcine and Human In Vivo Simulations for Doxorubicin-Containing Formulations Used in Locoregional Hepatocellular Carcinoma Treatment. AAPS Journal, 2018, 20, 96.	4.4	7
41	Optimized Experimental Design for the Estimation of Enzyme Kinetic Parameters: An Experimental Evaluation. Drug Metabolism and Disposition, 2012, 40, 2273-2279.	3.3	6
42	Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs. Journal of Pharmacy and Pharmacology, 2017, 69, 135-142.	2.4	6
43	Reply to â€œComment on â€˜In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically Based Absorption Modelsâ€™â€• Molecular Pharmaceutics, 2017, 14, 340-343.	4.6	6
44	Does the Intake of Ethanol Affect Oral Absorption of Poorly Soluble Drugs?. Journal of Pharmaceutical Sciences, 2019, 108, 1765-1771.	3.3	6
45	Binding Processes Determine the Stereoselective Intestinal and Hepatic Extraction of Verapamil in Vivo. Molecular Pharmaceutics, 2012, 9, 3034-3045.	4.6	5
46	Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs. European Journal of Pharmaceutical Sciences, 2014, 57, 214-223.	4.0	5
47	A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children. Pharmaceutics, 2021, 13, 204.	4.5	5
48	Does the choice of applied physiologicallyâ€based pharmacokinetics platform matter? A case study on simvastatin disposition and drugâ€“drug interaction. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1194-1209.	2.5	5
49	Hepatic Disposition of Ximelagatran and Its Metabolites in Pig; Prediction of the Impact of Membrane Transporters Through a Simple Disposition Model. Pharmaceutical Research, 2010, 27, 597-607.	3.5	3
50	Assessment of Free Drug Concentration in Cyclodextrin Formulations Is Essential to Determine Drug Potency in Functional InÂVitro Assays. Journal of Pharmaceutical Sciences, 2016, 105, 2913-2920.	3.3	3
51	The effect of intradermal microdosing of a transient receptor potential cation channel subfamily V member 1 antagonist on heat evoked pain and thermal thresholds in normal and ultravioletâ€ exposed skin in healthy volunteers. European Journal of Pain, 2019, 23, 1767-1779.	2.8	3
52	Reply to â€œComment on â€˜In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinomaâ€™â€• Molecular Pharmaceutics, 2018, 15, 336-340.	4.6	1